搜索结果

   SLC5A7

靶点ID:TCMBANKGE008048

靶点别名:CHT; CHT1; CMS20; HMN7A

靶点描述:solute carrier family 5 member 7

染色体:2

染色体位置:2q12.3

靶点类型:protein-coding

HERB_ID:-

HGNC_Link:14025

OMIM_Link:608761

Ensembl_Link:ENSG00000115665

   靶点对应的植物
ID 拉丁名 药名 药用植物名 功能与主治 来源 药用部位 使用民族
   靶点对应的化合物
化合物ID 化合物名 别名 分子式 分子质量 Smiles
TCMBANKIN000094 choline Choline chloride; choline hydroxide C5H14NO+ 104.17 g/mol C[N+](C)(C)CCO
TCMBANKIN008636 acetylcholine Vagusstoff; AC1NSTAT; Acetylcholine Hydroxide; 2-acetyloxyethyl(trimethyl)azanium hydroxide; SCHEMBL3904052; 56-13-3 C7H16NO2+ 146.21 g/mol CC(=O)OCC[N+](C)(C)C
TCMBANKIN036902 magnolol UPCMLD-DP037:001; UNII-001E35HGVF; 001E35HGVF; TR-031540; FT-0628104; SR-01000758206-3; AN-15430; 2'-Bichavicol; NSC 293099; MLS001048917; STK801955; KS-000009BG; ZINC00001645; [1,1'-Biphenyl]-2,2'-diol, 5,5'-di-2-propenyl-; 5,5'-bis(prop-2-en-1-yl)-[1,1'-biphenyl]-2,2'-diol; HMS3651O18; ZINC1645; PubChem19035; DS-1284; CTK1G9448; ST24029219; NCGC00161609-01; 2-(2-hydroxy-5-prop-2-enyl-phenyl)-4-prop-2-enyl-phenol; 5,5'-Di-2-propenyl-[1,1'-biphenyl]-2,2'-diol; HY-N0163; BN0720; 2-(2-hydroxy-5-prop-2-enylphenyl)-4-prop-2-enylphenol; MFCD00016658; SMP2_000086; SCHEMBL132477; 5,5'-Diallyl-2,2'-dihydroxybiphenyl; (1,1'-Biphenyl)-2,2'-diol, 5,5'-di-2-propenyl-; 3r5n; BC205200; Magnolol, European Pharmacopoeia (EP) Reference Standard; NSC293099; Magnolol, >=95% (HPLC), from plant; ACN-035415; SMR000387108; CM0085; Magnolol; NCGC00161609-02; magnolol ; MCULE-1351244567; AB0016717; VVOAZFWZEDHOOU-UHFFFAOYSA-N; 4-allyl-2-(5-allyl-2-hydroxy-phenyl)phenol; 2-[2-hydroxy-5-(prop-2-en-1-yl)phenyl]-4-(prop-2-en-1-yl)phenol; 5,5'-Diallyl-[1,1'-biphenyl]-2,2'-diol; 2-(2-oxidanyl-5-prop-2-enyl-phenyl)-4-prop-2-enyl-phenol; 528-43-8; 4-allyl-2-(5-allyl-2-hydroxyphenyl)phenol; HMS2269N09; Dehydrodichavicol; AC1Q7B1V; 4CN-0760; D3971; 5,5′-Diallyl-2,2′-biphenyldiol; BBL027818; s2321; 5,5'-Diallylbiphenyl-2,2'-diol; NSC-293099; KB-279770; CHEMBL180920; CCG-208588; AJ-08064; S-2836; 5,5'-Diallyl-2,2'-biphenyldiol; 5,5'-di(prop-2-en-1-yl)biphenyl-2,2'-diol; SR-01000758206; HSDB 7686; DTXSID0044076; AIDS-002239; BR-72952; CHEBI:6643; SC-25620; J10186; 5,5;-Diallyl-[1,1;-biphenyl]-2,2;-diol; M3445_SIGMA; UPCMLD-DP037; 528M438; BDBM78304; I01-2281; O906; Q-100598; AX8016874; LS-44356; AIDS002239; 2,2'-Bichavicol; BG00615874; Kopnolia; AC-931; N1359; SR-01000758206-4; AK-72952; MolPort-002-507-434; BB_NC-1463; Bio-0675; BRD-K26168087-001-01-4; RTR-031540; AKOS005266409; ZB000381; REGID_for_CID_72300; cid_72300; C-16714; C10651; AC1L2HT7; SY016075; CC-30123; CJ-00060; CS-5021 C18H18O2 266.334 C([H])([H])=C([H])C([H])([H])c1c([H])c([H])c(O[H])c(c2c([H])c(C([H])([H])C([H])=C([H])[H])c([H])c([H])c2O[H])c1[H]
TCMBANKIN058450 ADO nchembio.2007.56-comp13; CHEBI:16335; Bio1_000437; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; AIDS-001224; 9beta-D-Ribofuranosyladenine; BSPBio_001796; beta-Adenosine; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-methylol-tetrahydrofuran-3,4-diol; beta-D-Ribofuranoside, adenine-9; D00045; 46969-16-8; SDCCGMLS-0003108.P003; 4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 6-Amino-9-.beta.-ribofuranosyl-9H-purine; NSC 7652; Bio1_001415; Adenosine (JAN/USP); Spectrum2_001257; Spectrum3_000288; Adenosine, homopolymer; ADN; Caswell No. 010B; Adenocard; C00212; SR 96225; Adenocard (TN); EINECS 200-389-9; KBio3_001296; 9H-Purin-6-amine, 9beta-D-ribofuranosyl-; Polyadenosine; beta-D-Ribofuranose, 1-(6-amino-9H-purin-9-yl)-1-deoxy-; (2R,3R,4S,5R)-2-(6-amino-9-purinyl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; MLS000069638; AI3-52413; 9-beta-D-Ribofuranosidoadenine; A9251_SIGMA; Adenoscan (TN); Bio1_000926; ZINC02169830; CCRIS 2557; NCGC00023673-05; Ade-Rib; nchembio706-5; 30143-02-3; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; Adenosin [German]; NSC 627048; SMR000058216; 9-beta-D-Ribofuranosyladenine; SPBio_001194; beta-D-Adenosine; Adenosine [USAN:BAN]; Polyriboadenosine; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; AIDS001224; 6-Amino-9beta-D-ribofuranosyl-9H-purine; ST009496; Adenoscan; A4036_SIGMA; SPECTRUM1500107; 46946-45-6;SCHEMBL170902; adenosine ; AKOS015960342; AC-5504; BC200893; Adenosine;adenosine;adeninenucleoside C10H13N5O4 267.24 g/mol C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N
TCMBANKIN060645 lovastatin C24H36O5 404.5 g/mol CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C
   靶点对应的疾病
疾病ID 疾病名 MeSH名 HPO名 UMLS名 疾病类型
TCMBANKDI002718 - - Finding phenotype
TCMBANKDI004489 - Abnormality of the ear Congenital Abnormality disease
TCMBANKDI005771 - Abnormality of the musculature Cell or Molecular Dysfunction phenotype
TCMBANKDI007228 - - Finding phenotype
TCMBANKDI007343 Pathological Conditions, Signs and Symptoms; Nervous System Diseases - Finding phenotype
TCMBANKDI007707 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI007770 Pathological Conditions, Signs and Symptoms; Respiratory Tract Diseases Abnormality of the respiratory system Sign or Symptom phenotype
TCMBANKDI008007 - Abnormality of head or neck; Abnormality of the skeletal system Finding phenotype
TCMBANKDI008874 - Abnormality of head or neck Finding phenotype
TCMBANKDI009278 Mental Disorders - Mental or Behavioral Dysfunction group
TCMBANKDI013148 Respiratory Tract Diseases; Nervous System Diseases Abnormality of the nervous system; Abnormality of the respiratory system Disease or Syndrome disease
TCMBANKDI013994 Pathological Conditions, Signs and Symptoms; Nervous System Diseases Abnormality of the nervous system Finding phenotype
TCMBANKDI017869 Nervous System Diseases Abnormality of the nervous system; Abnormality of the musculature Disease or Syndrome disease
TCMBANKDI018929 Eye Diseases Abnormality of the eye Disease or Syndrome disease
TCMBANKDI018939 Pathological Conditions, Signs and Symptoms; Musculoskeletal Diseases; Nervous System Diseases Abnormality of the musculature Finding phenotype
TCMBANKDI019168 - Abnormality of the musculature Finding phenotype
TCMBANKDI019650 Pathological Conditions, Signs and Symptoms; Nervous System Diseases - Disease or Syndrome phenotype
TCMBANKDI020119 Mental Disorders Abnormality of the nervous system Finding phenotype
TCMBANKDI020574 Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Stomatognathic Diseases Abnormality of the nervous system; Abnormality of head or neck; Abnormality of the musculature Disease or Syndrome disease
TCMBANKDI021016 - - Organ or Tissue Function phenotype
TCMBANKDI022380 Female Urogenital Diseases and Pregnancy Complications Abnormality of prenatal development or birth Pathologic Function phenotype
TCMBANKDI022768 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases Abnormality of the skeletal system Congenital Abnormality disease
TCMBANKDI027248 Pathological Conditions, Signs and Symptoms; Musculoskeletal Diseases; Nervous System Diseases Abnormality of the musculature Finding phenotype
TCMBANKDI027721 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases Abnormality of the skeletal system; Abnormality of connective tissue; Abnormality of the musculature Disease or Syndrome disease
TCMBANKDI028664 - - Finding phenotype
TCMBANKDI029343 Pathological Conditions, Signs and Symptoms - Sign or Symptom phenotype
TCMBANKDI030194 Pathological Conditions, Signs and Symptoms; Respiratory Tract Diseases Abnormality of the respiratory system Pathologic Function phenotype
TCMBANKDI031189 Neoplasms Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI032109 Pathological Conditions, Signs and Symptoms - Disease or Syndrome disease

Home | Browse | Search | Predict | Data | Contact | Help

Copyright © KUST | 滇IICP备16009434号-1 | Dai SX Lab